Vandetanib
- Generic Name
- Vandetanib
- Brand Names
- Caprelsa
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24BrFN4O2
- CAS Number
- 443913-73-3
- Unique Ingredient Identifier
- YO460OQ37K
- Background
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
- Indication
Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.
- Associated Conditions
- Metastatic Thyroid Gland Medullary Carcinoma, Locally advanced Medullary thyroid cancer
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy with Gemcitabine Alone in Pancreatic Carcinoma
- First Posted Date
- 2012-05-18
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- University of Liverpool
- Target Recruit Count
- 142
- Registration Number
- NCT01601808
- Locations
- 🇬🇧
Belfast City Hospital, Belfast, United Kingdom
🇬🇧The Royal Bournemouth Hospital, Bournemouth, United Kingdom
🇬🇧Bristol Haematology and Oncology Centre, Bristol, United Kingdom
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
- Conditions
- Advanced Malignant NeoplasmMetastatic Malignant NeoplasmRecurrent Malignant NeoplasmRefractory Malignant Neoplasm
- Interventions
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 153
- Registration Number
- NCT01582191
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of Digoxin Administered Alone and in Combination With Vandetanib
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 14
- Registration Number
- NCT01561781
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
A Phase I Study to Assess the Pharmacokinetics of Metformin When Administered Alone and in Combination With Vandetanib
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 14
- Registration Number
- NCT01551615
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Study in Healthy Volunteers to Assess the Pharmacokinetics of Midazolam Administered Alone and in Combination With Vandetanib
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT01544140
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib
- Conditions
- Medullary Thyroid Cancer
- Interventions
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 34
- Registration Number
- NCT01539655
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 81
- Registration Number
- NCT01496313
- Locations
- 🇨🇿
Investigational Site Number : 1903, Olomouc, Czechia
🇨🇿Investigational Site Number : 1901, Praha, Czechia
🇵🇱Investigational Site Number : 5704, Warsaw, Mazowieckie, Poland
Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
- Conditions
- Precancerous ConditionLip and Oral Cavity Squamous Cell CarcinomaOral Cavity Verrucous Carcinoma
- Interventions
- Other: placeboOther: immunohistochemistry staining methodOther: laboratory biomarker analysisProcedure: biopsyOther: pharmacological study
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 20
- Registration Number
- NCT01414426
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Vandetanib to Treat Advanced Kidney Cancer
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT01372813
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
- Conditions
- Locally Advanced or Metastatic Medullary Thyroid CancerMedullary Thyroid Cancer
- Interventions
- Behavioral: Patient outreach
- First Posted Date
- 2011-02-17
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 205
- Registration Number
- NCT01298323
- Locations
- 🇦🇺
Investigational Site Number : 301, St Leonards, New South Wales, Australia
🇦🇹Investigational Site Number : 401, Wien, Austria
🇧🇪Investigational Site Number : 501, Anderlecht, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.